After treatment with denosumab, how long is there a risk of mandibular osteonecrosis in a dental implant?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18289370
Cited by: 0

Abstract

The risk of mandibular osteonecrosis following denosumab treatment persists for an undefined period, with reports suggesting it can occur years after treatment initiation, particularly in cancer patients.

Fields of Study & Subjects

Bone health and treatments Oral health in cancer treatment Dental Implant Techniques and Outcomes

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
18 January 2026